Commenting on the Government’s announcement today (14 July 2017) regarding funding for the Accelerated Access Review (AAR), BIVDA’s Chief Executive, Doris-Ann Williams MBE, said:
"BIVDA very much welcomes the Government's announcement about funding towards practical support for the introduction of new medical technologies into the NHS.
“It is a constant source of frustration that implementation of new tests takes years to achieve; it means that not only are people not benefitting from improved diagnosis and disease management but also that the NHS is losing the chance to gain cost efficiencies along clinical pathways.
"The fifteen Academic Health Science Networks (AHSNs) are now established and working locally on projects but we hope this additional funding will enable them to better support spread across the NHS and more equitable access for patients to new tests and technologies.
"A particular issue for IVDs is the complication of getting them embedded into clinical pathways and indeed, making the changes to pathways and tariffs to enable their use. This is true for all IVDs from those used at the point of care to the most sophisticated molecular tests which enable exquisitely tailored treatment; diagnostic dependent drugs.
"Along with other life science sectors, the use of digital technologies will be critical to enable the best function of many IVDs, such as the diagnostic tools which will support self-care by people with long term conditions or such as the implementation of digital pathology systems. So the creation of the digital health catalyst is a welcome inclusion in today's funding announcement."
"And with a large number of SME companies in the IVD sector, extra support for these organisations is always welcome news".
"We would like to congratulate the Department of Health and the Department for Business, Energy and Industrial Strategy on pulling together these funding streams ahead of the Industrial Strategy to show practical support of their intent to foster healthy and vibrant Life Sciences industries in the UK."
Notes to Editor:
BIVDA is the industry association for manufacturers and suppliers of IVD tests. We represent over 100 members, ranging from British start-up companies to UK subsidiaries of multinational corporations. BIVDA member companies employ more than 8,000 people in the UK, with total industry sales to the NHS of approximately £850 million.
For further information, please contact External Affairs Manager Emma Thomas at email@example.com or 0845 6188224.